The decreased CD11b+ Ly6Chigh M-MDSCs may contribute to the clinical anti-tumor action of RPM treatment, which offers new cellular mechanisms for RPM to treat cancers in addition to its direct inhibitory effects on tumor cells. The gene discussed is ITGAM; the disease is neoplasm.